Jonsson Comprehensive Cancer Center
🇺🇸United States
Clinical Trials
375
Active:40
Completed:164
Trial Phases
6 Phases
Early Phase 1:17
Phase 1:109
Phase 2:114
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (338 trials with phase data)• Click on a phase to view related trials
Phase 2
114 (33.7%)Phase 1
109 (32.2%)Not Applicable
80 (23.7%)Early Phase 1
17 (5.0%)Phase 3
17 (5.0%)Phase 4
1 (0.3%)Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Not Applicable
Recruiting
- Conditions
- Anal CarcinomaBladder CarcinomaBreast CarcinomaCervical CarcinomaCholangiocarcinomaColorectal CarcinomaEsophageal CarcinomaGastric CarcinomaHead and Neck CarcinomaHematopoietic and Lymphatic System Neoplasm
- First Posted Date
- 2025-08-12
- Last Posted Date
- 2025-08-12
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT07118176
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
ERAS-801 for the Treatment of Resectable and Progressive or Recurrent IDH Wildtype Grade IV Glioblastoma or Astrocytoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
Not Applicable
Recruiting
- Conditions
- Recurrent AstrocytomaIDH Wildtype GlioblastomaIDH Wildtype Recurrent GlioblastomaResectable AstrocytomaResectable Glioblastoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Echocardiography TestDrug: EGFR Inhibitor ERAS-801Other: Fludeoxyglucose F-18Procedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyProcedure: Surgical Procedure
- First Posted Date
- 2025-07-28
- Last Posted Date
- 2025-08-01
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT07089641
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Prostate Cancer Postoperative Stereotactic Body Radiotherapy With Adaptive Technology for Minimizing Toxicity
Recruiting
- Conditions
- Prostate Cancer (CRPC)
- First Posted Date
- 2025-07-22
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 200
- Registration Number
- NCT07077239
- Locations
- 🇺🇸
University of California at Los Angeles, Los Angeles, California, United States
A Disposable Negative Pressure Wound Therapy Device (SNaP) to Promote Wound Healing in the Lower Limbs Following Mohs Micrographic Surgery for Non-melanoma Skin Cancer
Not Applicable
Not yet recruiting
- Conditions
- Skin Carcinoma
- First Posted Date
- 2025-06-24
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT07032701
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Computed Tomography-Guided Stereotactic Body Radiation Therapy With Intrafraction Motion Monitoring for the Treatment of Localized Prostate Cancer, ILLUSION Trial
Not Applicable
Not yet recruiting
- Conditions
- Localized Prostate AdenocarcinomaStage I Prostate Cancer AJCC v8Stage II Prostate Cancer AJCC v8Stage III Prostate Cancer AJCC v8
- First Posted Date
- 2025-05-29
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 80
- Registration Number
- NCT06995053
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 75
- Next
News
No news found